-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

To Transplant or Not to Transplant in Active or High Risk Myeloid Disease

Program: Education Program
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, AML, MDS, Translational Research, Workforce, Combination therapy, Clinical Research, Diversity, Equity, and Inclusion (DEI) , Chronic Myeloid Malignancies, Diseases, Therapies, Myeloid Malignancies, Minimal Residual Disease
Monday, December 12, 2022: 4:30 PM-5:45 PM
343-345 (Ernest N. Morial Convention Center)
Chair:
Coleman Lindsley, MD, PhD, Dana-Farber Cancer Institute
Disclosures:
Lindsley: Thermo Fisher: Consultancy; Nuprobe: Consultancy; Qiagen: Consultancy; bluebird bio: Consultancy; Takeda Pharmaceuticals: Consultancy.
Transplant in Those with High Burden Disease: Refractory AML and High Risk MDS

Daniel J. Weisdorf, MD

Hematology/Oncology and Transplant, University of Minnesota, Minneapolis, MN
Transplant in AML with Measurable Residual Disease: Proceed or Defer?

Charles Craddock

Queen Elizabeth Hospital, Birmingham, ENG, United Kingdom
Transplant for TP53-Mutated MDS and AML: Because We Can or Because We Should?

Coleman Lindsley, MD, PhD

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
See more of: Education Program
<< Previous Session | Next Session >>